AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10232431 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated pulmonary stenosis (PS) children during exercise
Number of subjects: 117
Study 10232431 — intervention group
Group type: COMPARATOR
Intervention: Control children during exercise
Number of subjects: 117
Study 8290676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (FZD)
Number of subjects: 208
Study 3825935 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg slow-release IS-5MN
Number of subjects: 9
Study 3825935 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg slow-release IS-5MN
Number of subjects: 9
Study 3825935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28857848 — intervention group
Group type: COMPARATOR
Intervention: IV amikacin 20 mg/kg once daily
Number of subjects: 133
Study 28857848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin 400 mg twice daily
Number of subjects: 133
Study 27412108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylnaltrexone
Number of subjects: 84
Study 27412108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 25880761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) transfusion (12 ml/kg)
Number of subjects: 33
Study 23469933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasma enucleation of the prostate (BPEP)
Number of subjects: 140
Study 23469933 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 140
Study 21613358 — intervention group
Group type: EXPERIMENTAL
Intervention: 72‐h fasting
Number of subjects: 8
Study 21613358 — intervention group
Group type: COMPARATOR
Intervention: 1‐h exercise (65% VO(2max))
Number of subjects: 8
Study 21613358 — intervention group
Group type: COMPARATOR
Intervention: Basal state
Number of subjects: 8
Study 19100647 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/gemcitabine (IG) regimen (gemcitabine 1000mg/m² i.v. on days 1 and 8 and irinotecan 300mg/m² i.v. on day 8) every 3 weeks
Number of subjects: 69
Study 19100647 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (I) monotherapy (300mg/m² i.v. on day 1) every 3 weeks
Number of subjects: 69
Study 19100647 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/gemcitabine (IG) regimen
Number of subjects: 69
Study 19100647 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (I) monotherapy
Number of subjects: 69
Study 16720794 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 16720794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15304299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype sports drink containing calcium and maltodextrin
Number of subjects: 18
Study 15304299 — intervention group
Group type: COMPARATOR
Intervention: Drink with calcium (positive control)
Number of subjects: 18
Study 15304299 — intervention group
Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 18
Study 11765070 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (morphine)
Number of subjects: 43
Study 11765070 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TC)
Number of subjects: 43
Study 10541229 — intervention group
Group type: EXPERIMENTAL
Intervention: Selfotel (CGS 19755)
Number of subjects: 693
Study 10541229 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 693
Study 8024947 — intervention group
Group type: EXPERIMENTAL
Intervention: Single enantiomer formulation (SEF) of (S)-atenolol, 50 mg
Number of subjects: 8
Study 8024947 — intervention group
Group type: COMPARATOR
Intervention: Racemic mixture (Tenormin, TMN) of (R,S)-atenolol, 100 mg
Number of subjects: 8
Study 8024947 — intervention group
Group type: EXPERIMENTAL
Intervention: Single enantiomer formulation (SEF) of (S)-atenolol
Number of subjects: 8
Study 8024947 — intervention group
Group type: COMPARATOR
Intervention: Racemic mixture (Tenormin, TMN) of (R,S)-atenolol
Number of subjects: 8
Study 2584565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion
Number of subjects: 12
Study 2584565 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 5823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with low dose progestogen and high dose oestrogen
Number of subjects: 0
Study 5823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential oral contraceptives
Number of subjects: 0
Study 5823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogenic combined preparations
Number of subjects: 0
Study 5823051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogenic sequential regimens and low-dose progestogen-only regimens
Number of subjects: 0
Study 31846029 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Number of subjects: 37
Study 31846029 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and Feedback with Peer Norm Comparison
Number of subjects: 37
Study 31846029 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to either intervention)
Number of subjects: 37
Study 30556470 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad Brush Survey (BBS) approach
Number of subjects: 0
Study 28737466 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous mutant of rs1501299
Number of subjects: 0
Study 28737466 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous mutant of rs2241766
Number of subjects: 0
Study 28737466 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous mutant of rs7649121
Number of subjects: 0
Study 28737466 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with rs1501299-GT or TT genotype
Number of subjects: 0
Study 26385346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal S. salivarius 24SMB
Number of subjects: 100
Study 26385346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26385346 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonized children with S. salivarius 24SMB
Number of subjects: 100
Study 26385346 — intervention group
Group type: COMPARATOR
Intervention: Non-colonized children
Number of subjects: 100
Study 26385346 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonized children treated with antibiotics
Number of subjects: 100
Study 26385346 — intervention group
Group type: COMPARATOR
Intervention: Non-colonized children treated with antibiotics
Number of subjects: 100
Study 24217026 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule A containing artificial food colorings (AFCs)
Number of subjects: 130
Study 24217026 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule B containing sodium benzoate
Number of subjects: 130
Study 24217026 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 130
Study 21472442 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants perceived as belonging to the same group (ingroup) during the Simon task
Number of subjects: 0
Study 21472442 — intervention group
Group type: COMPARATOR
Intervention: Participants perceived as belonging to a different group (outgroup) during the Simon task
Number of subjects: 0
Study 21472442 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants experiencing positive interdependence during the Simon task
Number of subjects: 0
Study 21472442 — intervention group
Group type: COMPARATOR
Intervention: Participants experiencing negative interdependence during the Simon task
Number of subjects: 0
Study 18838526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI breakfast
Number of subjects: 21
Study 18838526 — intervention group
Group type: COMPARATOR
Intervention: High GI breakfast
Number of subjects: 21
Study 16426468 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg 6 hourly
Number of subjects: 60
Study 16426468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12802822 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving dental care
Number of subjects: 0
Study 12802822 — intervention group
Group type: COMPARATOR
Intervention: Not receiving dental care
Number of subjects: 0
Study 11016670 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulfate patch tests with various doses and vehicles
Number of subjects: 16
Study 11016670 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial-dose series for time intervals ranging from 3 to 96 h
Number of subjects: 16
Study 11016670 — intervention group
Group type: COMPARATOR
Intervention: Visual assessments
Number of subjects: 16
Study 9177881 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 14
Study 9177881 — intervention group
Group type: COMPARATOR
Intervention: Control (no anisodamine)
Number of subjects: 14
Study 8104509 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.2 mg/kg)
Number of subjects: 0
Study 8104509 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 0
Study 8104509 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol challenge
Number of subjects: 0
Study 8104509 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquin (peripheral monoamine oxidase inhibitor)
Number of subjects: 0
Study 8104509 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 2425168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.0125-0.50 micrograms/kg/min)
Number of subjects: 18
Study 2425168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (0.05-0.3 mg/kg, bolus injections)
Number of subjects: 18
Study 2425168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 18
Study 2425168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 18
Study 29561783 — intervention group
Group type: EXPERIMENTAL
Intervention: MK7 (360 mcg/day)
Number of subjects: 44
Study 29561783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 26611780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius PS2 (9 log10 colony‐forming units daily from week 30 of pregnancy until delivery)
Number of subjects: 108
Study 26611780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 26611780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius PS2
Number of subjects: 108
Study 24533064 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N3 live attenuated influenza vaccine
Number of subjects: 40
Study 24533064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23052711 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 187
Study 23052711 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 187
Study 19687293 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX)
Number of subjects: 0
Study 19687293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18504215 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human brain natriuretic peptide (rhBNP)
Number of subjects: 50
Study 18504215 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 50
Study 15944888 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of the axial rotation moment to correct asymmetric efforts
Number of subjects: 89
Study 15944888 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain subjects
Number of subjects: 89
Study 15944888 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 89
Study 15944888 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized EMG imbalance parameters
Number of subjects: 89
Study 15944888 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG imbalance parameters
Number of subjects: 89
Study 15944888 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back status and pain location
Number of subjects: 89
Study 12355220 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 30
Study 12355220 — intervention group
Group type: COMPARATOR
Intervention: Conventional colorectal resection
Number of subjects: 30
Study 10609635 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared-controlled computer interface using tongue-touch circuitry and low power laser (<0.1 mW) beam.
Number of subjects: 0
Study 8941177 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 32
Study 8941177 — intervention group
Group type: COMPARATOR
Intervention: Absorbable gelatine sponge (Gelfoam)
Number of subjects: 32
Study 1837510 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-sized lunch with reduced insulin dose
Number of subjects: 43
Study 1837510 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed evening meal
Number of subjects: 43
Study 1837510 — intervention group
Group type: COMPARATOR
Intervention: Control meal (normal meals)
Number of subjects: 43
Study 7028238 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in low dose + Methylphenidate
Number of subjects: 6
Study 7028238 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in low dose
Number of subjects: 6
Study 7028238 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose caffeine
Number of subjects: 6
Study 7028238 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no-drug conditions
Number of subjects: 6
Study 30475722 — intervention group
Group type: EXPERIMENTAL
Intervention: Remind-to-Move (RTM) using wearable devices for three consecutive hours daily over four weeks
Number of subjects: 84
Study 30475722 — intervention group
Group type: COMPARATOR
Intervention: Sham devices
Number of subjects: 84
Study 30475722 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 84
Study 28062537 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 180
Study 28062537 — intervention group
Group type: COMPARATOR
Intervention: Heart Failure Education
Number of subjects: 180
Study 26958310 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention with outreach visits
Number of subjects: 14847
Study 26958310 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14847
Study 23663298 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow needle puncture method
Number of subjects: 600
Study 20568955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metformin-clomiphene citrate (CC)
Number of subjects: 153
Study 20568955 — intervention group
Group type: COMPARATOR
Intervention: Highly purified urinary FSH (HP-uFSH)
Number of subjects: 153
Study 20014600 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion (20 ng kg(‐1) min(‐1))
Number of subjects: 30
Study 20014600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Number of subjects: 30
Study 17470271 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 18
Study 17470271 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 18
Study 14756915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dephytinised soya formula (<6 mg phytic acid/kg liquid formula)
Number of subjects: 9
Study 14756915 — intervention group
Group type: COMPARATOR
Intervention: Regular soya formula (300 mg phytic acid/kg liquid formula)
Number of subjects: 9
Study 11716197 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma nurse intervention during hospitalization
Number of subjects: 80
Study 11716197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no asthma nurse intervention)
Number of subjects: 80
Study 8986681 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/d tibolone (n = 15)
Number of subjects: 29
Study 8986681 — intervention group
Group type: COMPARATOR
Intervention: Iron pill (placebo, n = 14)
Number of subjects: 29
Study 8503809 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 24
Study 8503809 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg
Number of subjects: 24
Study 8503809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3552107 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiggling allowed
Number of subjects: 21
Study 3552107 — intervention group
Group type: COMPARATOR
Intervention: Jiggling not allowed
Number of subjects: 21
Study 30474191 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes with cirrhosis
Number of subjects: 154
Study 30474191 — intervention group
Group type: COMPARATOR
Intervention: Diabetes without cirrhosis
Number of subjects: 154
Study 30522667 — intervention group
Group type: EXPERIMENTAL
Intervention: Restore paclitaxel‐coated balloon (DCB)
Number of subjects: 230
Study 30522667 — intervention group
Group type: COMPARATOR
Intervention: RESOLUTE Integrity drug-eluting stent (DES)
Number of subjects: 230
Study 26849017 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 120
Study 26849017 — intervention group
Group type: EXPERIMENTAL
Intervention: 30° head up position
Number of subjects: 120
Study 26849017 — intervention group
Group type: EXPERIMENTAL
Intervention: 45° head up position
Number of subjects: 120
Study 26849017 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger group (1-8 years)
Number of subjects: 120
Study 26849017 — intervention group
Group type: EXPERIMENTAL
Intervention: Older group (9-16 years)
Number of subjects: 120
Study 26849017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 120
Study 24376274 — intervention group
Group type: EXPERIMENTAL
Intervention: JTT-751 (1.5 to 6.0 g/day)
Number of subjects: 230
Study 24376274 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (3.0 to 9.0 g/day)
Number of subjects: 230
Study 24376274 — intervention group
Group type: EXPERIMENTAL
Intervention: JTT-751
Number of subjects: 230
Study 24376274 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride
Number of subjects: 230
Study 21984532 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of twice weekly, 60-minute group exercise sessions, including mobility, balance and resistance exercises.
Number of subjects: 32
Study 21984532 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 32
Study 20506062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (INCB‐018424)
Number of subjects: 0
Study 20506062 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream formulation of Ruxolitinib
Number of subjects: 0
Study 18397484 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week pegIFN-alpha-2a therapy
Number of subjects: 55
Study 18397484 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week pegIFN-alpha-2a therapy
Number of subjects: 55
Study 15850095 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release (CTR) surgery
Number of subjects: 0
Study 12408198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced EFNEP intervention arm (Usual WIC Care plus a sustained, multi-component intervention including home visits, group classes and monthly telephone counseling)
Number of subjects: 0
Study 12408198 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (WIC nutrition and breastfeeding education)
Number of subjects: 0
Study 10479202 — intervention group
Group type: EXPERIMENTAL
Intervention: Weanimix (W)
Number of subjects: 208
Study 10479202 — intervention group
Group type: EXPERIMENTAL
Intervention: Weanimix plus vitamins and minerals (WM)
Number of subjects: 208
Study 10479202 — intervention group
Group type: EXPERIMENTAL
Intervention: Weanimix plus fish powder (WF)
Number of subjects: 208
Study 10479202 — intervention group
Group type: EXPERIMENTAL
Intervention: Koko plus fish powder (KF)
Number of subjects: 208
Study 10479202 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (NI)
Number of subjects: 208
Study 8569363 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse-chestnut seed extract (HCSE, 50 mg aescin, twice daily)
Number of subjects: 240
Study 8569363 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings class II
Number of subjects: 240
Study 8569363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 1722443 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet amyloid polypeptide infusion (150 pmol min‐1 kg‐1)
Number of subjects: 5
Study 1722443 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin infusion (50 pmol min‐1 kg‐1)
Number of subjects: 5
Study 6180901 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine alone
Number of subjects: 0
Study 6180901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of triprolidine and pseudoephedrine
Number of subjects: 0
Study 6180901 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine alone
Number of subjects: 0
Study 6180901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6180901 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine vs Combination
Number of subjects: 0
Study 31952305 — intervention group
Group type: EXPERIMENTAL
Intervention: Past experiences in actively initiating DNR discussions with patients or patients’ families
Number of subjects: 132
Study 31952305 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 20.0 to 29.9 years
Number of subjects: 132
Study 31952305 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of actively initiated DNR or LST discussions with patients’ families
Number of subjects: 132
Study 31952305 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience in actively initiating discussions about LST withdrawal with patients’ families
Number of subjects: 132
Study 31952305 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male and possessing an education level higher than university
Number of subjects: 132
Study 30823945 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide combined with insulin
Number of subjects: 92
Study 30823945 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (Control)
Number of subjects: 92
Study 27632846 — intervention group
Group type: EXPERIMENTAL
Intervention: BAPS rehabilitation program (3 times/week for 4 weeks)
Number of subjects: 22
Study 27632846 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 22